![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC45A2 |
Gene summary for SLC45A2 |
![]() |
Gene information | Species | Human | Gene symbol | SLC45A2 | Gene ID | 51151 |
Gene name | solute carrier family 45 member 2 | |
Gene Alias | 1A1 | |
Cytomap | 5p13.2 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9UMX9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51151 | SLC45A2 | HCC1_Meng | Human | Liver | HCC | 1.89e-05 | -9.99e-04 | 0.0246 |
51151 | SLC45A2 | HCC1 | Human | Liver | HCC | 1.17e-09 | 2.02e+00 | 0.5336 |
51151 | SLC45A2 | S014 | Human | Liver | HCC | 4.58e-05 | 1.51e-01 | 0.2254 |
51151 | SLC45A2 | S015 | Human | Liver | HCC | 9.93e-11 | 2.72e-01 | 0.2375 |
51151 | SLC45A2 | S016 | Human | Liver | HCC | 4.66e-16 | 5.58e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19016172 | Liver | HCC | organic hydroxy compound biosynthetic process | 129/7958 | 237/18723 | 1.32e-04 | 1.08e-03 | 129 |
GO:0042440 | Liver | HCC | pigment metabolic process | 51/7958 | 84/18723 | 5.74e-04 | 3.65e-03 | 51 |
GO:0046148 | Liver | HCC | pigment biosynthetic process | 37/7958 | 62/18723 | 4.73e-03 | 2.02e-02 | 37 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC45A2 | SNV | Missense_Mutation | novel | c.415G>C | p.Val139Leu | p.V139L | Q9UMX9 | protein_coding | deleterious(0.04) | benign(0.014) | TCGA-55-5899-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR |
SLC45A2 | SNV | Missense_Mutation | c.1286N>A | p.Ser429Asn | p.S429N | Q9UMX9 | protein_coding | deleterious(0.01) | possibly_damaging(0.601) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC45A2 | SNV | Missense_Mutation | novel | c.1357G>A | p.Glu453Lys | p.E453K | Q9UMX9 | protein_coding | tolerated(0.37) | benign(0.015) | TCGA-73-7498-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | pemetrexed | CR |
SLC45A2 | SNV | Missense_Mutation | novel | c.842C>A | p.Pro281Gln | p.P281Q | Q9UMX9 | protein_coding | tolerated(0.09) | benign(0.005) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
SLC45A2 | SNV | Missense_Mutation | c.635N>T | p.Gly212Val | p.G212V | Q9UMX9 | protein_coding | deleterious(0.02) | probably_damaging(0.92) | TCGA-93-7348-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC45A2 | SNV | Missense_Mutation | c.773C>A | p.Pro258His | p.P258H | Q9UMX9 | protein_coding | tolerated(0.3) | benign(0.152) | TCGA-95-A4VP-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
SLC45A2 | SNV | Missense_Mutation | novel | c.1535N>G | p.Ser512Cys | p.S512C | Q9UMX9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-99-8033-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
SLC45A2 | SNV | Missense_Mutation | novel | c.1417N>T | p.Gly473Cys | p.G473C | Q9UMX9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-NJ-A4YF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC45A2 | SNV | Missense_Mutation | c.290N>G | p.Ser97Cys | p.S97C | Q9UMX9 | protein_coding | tolerated(0.11) | benign(0.05) | TCGA-21-1077-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SLC45A2 | SNV | Missense_Mutation | c.290N>G | p.Ser97Cys | p.S97C | Q9UMX9 | protein_coding | tolerated(0.11) | benign(0.05) | TCGA-22-0940-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |